Opdivo (Nivolumab) vs Exkivity (mobocertinib)
Opdivo (Nivolumab) vs Exkivity (mobocertinib)
Opdivo (nivolumab) is an immune checkpoint inhibitor specifically designed to harness the body's immune system to help fight cancer, and it is commonly used for various types of cancers, including melanoma, lung cancer, and kidney cancer. Exkivity (mobocertinib) is a targeted therapy known as a tyrosine kinase inhibitor, which is used for the treatment of non-small cell lung cancer with specific mutations (EGFR exon 20 insertion mutations) and is not a broad immune system activator like Opdivo. The choice between Opdivo and Exkivity would depend on the specific type and genetic characteristics of the cancer; therefore, a healthcare provider would recommend one over the other based on the patient's unique cancer profile and overall health condition.
Difference between Opdivo and Exkivity
| Metric | Opdivo (Nivolumab) | Exkivity (mobocertinib) |
|---|---|---|
| Generic name | Nivolumab | Mobocertinib |
| Indications | Various types of cancers including melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and more. | Non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertion mutations. |
| Mechanism of action | Programmed death receptor-1 (PD-1) blocking antibody. | Tyrosine kinase inhibitor targeting EGFR Exon 20 insertion mutations. |
| Brand names | Opdivo | Exkivity |
| Administrative route | Intravenous infusion | Oral |
| Side effects | Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, and others. | Diarrhea, rash, nausea, vomiting, and others. |
| Contraindications | Patients with hypersensitivity to nivolumab or any of its excipients. | Patients with hypersensitivity to mobocertinib or any of its excipients. |
| Drug class | Immune checkpoint inhibitor | Tyrosine kinase inhibitor |
| Manufacturer | Bristol-Myers Squibb | Takeda Pharmaceutical Company |
Efficacy
Efficacy of Opdivo (Nivolumab) in Lung Cancer
Opdivo (Nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody used in the treatment of various forms of cancer, including lung cancer. In the context of non-small cell lung cancer (NSCLC), Opdivo has demonstrated significant efficacy, particularly in patients who have previously been treated with chemotherapy. Clinical trials have shown that Opdivo can extend overall survival compared to traditional chemotherapy agents. For example, in the CheckMate-057 study, patients with advanced NSCLC who were treated with Opdivo experienced a median overall survival of 12.2 months, compared to 9.4 months in those treated with docetaxel. The response rate was also higher with Opdivo, suggesting a substantial benefit for patients with this type of lung cancer.
Opdivo's efficacy is also notable in small cell lung cancer (SCLC), where it has been used after the failure of first-line therapy. In studies, Opdivo has shown to prolong survival in SCLC patients, although the improvement in survival is modest. The CheckMate-032 trial indicated that nivolumab monotherapy resulted in durable responses and a manageable safety profile in patients with relapsed SCLC. These results have led to the adoption of Opdivo in various treatment regimens for lung cancer, highlighting its role as a valuable therapeutic option in this disease.
Efficacy of Exkivity (mobocertinib) in Lung Cancer
Exkivity (mobocertinib) is a kinase inhibitor specifically designed to target EGFR Exon20 insertion mutations in non-small cell lung cancer (NSCLC). This mutation is a driver of oncogenic activity in a subset of NSCLC and is associated with poor prognosis and limited treatment options. Exkivity has shown promising efficacy in patients with NSCLC harboring these mutations. In the pivotal phase 1/2 trial, which led to its approval, mobocertinib demonstrated a response rate of approximately 28% in previously treated patients with EGFR Exon20 insertion-positive NSCLC. The median duration of response was also notable, with patients experiencing a median of 17.5 months.
Exkivity's approval was based on the results of this trial, which provided a new treatment option for patients with this challenging mutation who have few effective therapies available. The targeted nature of mobocertinib means that its efficacy is specific to the presence of the EGFR Exon20 insertion mutation, and it represents a significant advancement in personalized medicine for lung cancer. As such, Exkivity is a critical addition to the armamentarium against NSCLC, particularly for patients with the specified genetic alterations.
Regulatory Agency Approvals
Opdivo
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Exkivity
-
Food and Drug Administration (FDA), USA
Access Opdivo or Exkivity today
If Opdivo or Exkivity are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us